Research
Epitranscriptomics & Cancer Adaptation : A.David

Activities

Our research work focuses on the contribution of post-transcriptional mechanisms on cancer cell adaptation, in particular RNA epigenetic & translational control.

More..

Zotero public









Cancel


16 Items
Title  Creator  Group name  Publishing year 
Phase II study evaluating the association of gemcitabine, trastuzumab and erlotinib as first-line treatment in patients with metastatic pancreatic adenocarcinoma (GATE 1) Assenat et al. EquipeMY 2021-02-01
Limitations of the PRODIGE 7 trial - Authors' reply Quénet et al. EquipePM 2021-05
Importance of Patient Education for At-home Yoga Practice in Women With Hormonal Therapy-induced Pain During Adjuvant Breast Cancer Treatment: A Feasibility Study Faravel et al. EquipeCTCS 2021 Jan-Dec
Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial Quénet et al. EquipePM 2021-02
Changes in vitamin D and calcium metabolism markers in patients undergoing adjuvant chemotherapy for breast cancer Viala et al. EquipeCTCS 2021-07-15
[Not Available] Lacroix et al. EquipeAD 2020
A double-blind phase III trial of immunomodulating nutritional formula during adjuvant chemoradiotherapy in head and neck cancer patients: IMPATOX Boisselier et al. EquipeAD Sep 16, 2020
Sorafenib alone vs. sorafenib plus GEMOX as 1st-line treatment for advanced HCC: the phase II randomised PRODIGE 10 trial Assenat et al. EquipeMY Apr 04, 2019
Assessing dietary intake in accordance with guidelines: Useful correlations with an ingesta-Verbal/Visual Analogue Scale in medical oncology patients Guerdoux-Ninot et al. EquipeAD 2019-08
Artificial nutrition in patients with cancer has no impact on tumour glucose metabolism: Results of the PETANC Study Deshayes et al. EquipeAD Oct 2019
Two-stage hepatectomy for colorectal liver metastases: Pathologic response to preoperative chemotherapy is associated with second-stage completion and longer survival Quénet et al. EquipeMY Nov 16, 2018
Robotic Versus Laparoscopic Total Mesorectal Excision for Sphincter-Saving Surgery: Results of a Single-Center Series of 400 Consecutive Patients and Perspectives Rouanet et al. EquipeCTCS Nov 2018
Management of Cancer Cachexia and Guidelines Implementation in a Comprehensive Cancer Center: A Physician-Led Cancer Nutrition Program Adapted to the Practices of a Country Senesse et al. EquipeAD 09 2017
Reproductive Decision-Making in MMR Mutation Carriers After Results Disclosure: Impact of Psychological Status in Childbearing Options Duffour et al. EquipeMY 06 2016
A phase III study evaluating oral glutamine and transforming growth factor-beta 2 on chemotherapy-induced toxicity in patients with digestive neoplasm Khemissa et al. EquipeAD 2016-03
Feasibility and tolerability of self-insertion of a transnasal tube for esophagogastroduodenoscopy: a pilot study Senesse et al. EquipeAD 2015
16 Items


Who are we ?

Located in the Parc Euromédecine, the Institut de Recherche en Cancérologie de Montpellier (U1194) is located on the Val d'Aurelle Campus (ICM, Institut régional du Cancer Montpellier/ Val d'Aurelle).

U1194 Research Centre supported by Inserm, the University of Montpellier and the Institut du Cancer de Montpellier (ICM)

More                                                                                                                 Join us

Contact us

Institut de Recherche en Cancérologie de
Montpellier (U1194) - Campus Val d'Aurelle

208 avenue des Apothicaires
34298 Montpellier cedex 5 FRANCE

 

insermUM1ICM

© Institut de Recherche en Cancérologie de Montpellier - 2011 - Tous droits réservés - Mentions légales - Connexion - Conception : ID Alizés